Request Sample
Request Methodology
Description
Europe Hemostasis Diagnostics Market size was valued at USD 1,057.50 million in 2021 and is expected to reach USD 1,970.20 million in 2028 at a CAGR of 9.3% from 2022-2028. Hemostasis diagnostics are the devices used to determine the hemostatic defects, which cause excessive bleeding. Hemostasis is defined as the stopping or slowing the blood flow from damaged blood vessel. During the hemostasis, blood changes from liquid state to the gelatinous state. Hemostasis maintained in the body by three mechanisms namely, blood coagulation, platelet plug formation, and vasoconstriction. Hemostasis diagnostics may help to predict the cause of bleeding during surgery by identifying the hemostatic defects in patients. Different types of tests such as prothrombin test, activated clotting time, platelet function, and other coagulation tests are carried to identify the hemostasis defects. Increase in the prevalence of hemostasis related disease in Europe countries (according to The European National Registry of Congenital Coagulopathies 2017, the number of cases identified with hemostasis is increased from 7000 in 2000 to 11,000 in 2015), rise in number of surgery cases, rise in R&D investment for novel tests and devices innovation, and well developed healthcare infrastructure are expected to boost the hemostasis diagnostics market. However, high cost of advanced hemostasis products, and stringent regulations for the test approvals are expected to hamper the growth of hemostasis diagnostics market. This market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.
